Tuberculosis, Lung Infections, and Respiratory Care

Advances in Tuberculosis Diagnosis

Recent years have witnessed significant progress in the diagnosis of tuberculosis (TB), driven by innovations in molecular biology, digital technology, and laboratory science. These advances have improved the speed, accuracy, and accessibility of TB detection, contributing to earlier treatment initiation and better disease control. One major breakthrough is the development of rapid molecular diagnostic tools such as Gene pert MTB/RIF and its successor, Xpert Ultra. These tests can detect Mycobacterium tuberculosis DNA and rifampicin resistance within a few hours, offering a powerful alternative to traditional culture methods that may take weeks. Similarly, next-generation sequencing (NGS) technologies are now being used to identify drug-resistance mutations across multiple TB drugs simultaneously, enabling more precise and individualized treatment regimens.

In addition, novel point-of-care assays and portable molecular platforms have expanded diagnostic capabilities in resource-limited settings. Advances in biomarker research—such as host gene expression signatures, antigen detection, and volatile organic compound analysis—are opening new possibilities for non-sputum-based testing, which is especially valuable for diagnosing TB in children and people living with HIV.Digital radiography combined with artificial intelligence (AI) algorithms has also improved the interpretation of chest X-rays, providing automated screening tools that enhance case detection in large populations.